-

Dexcom Announces Upcoming Virtual Conference Presentations

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on Dexcom at the following upcoming virtual investor conferences:

  • Steve Pacelli, Executive Vice President Strategy and Corporate Development will present on behalf of the company at the Stifel Virtual Healthcare Conference on Monday, November 16, 2020 at 11:20am (EST).
  • Steve Pacelli, Executive Vice President Strategy and Corporate Development will present on behalf of the company at the Piper Sandler Healthcare Conference on Tuesday, December 1, 2020 at 3:00pm (EST).

Links to the webcasts will be available on the Dexcom Investor Relations website at investors.dexcom.com/ and will be archived there for future reference.

About DexCom, Inc.

DexCom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) products. Headquartered in San Diego, California, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of patients, caregivers, and clinicians, Dexcom simplifies and improves diabetes management around the world.

Contacts

DexCom, Inc.
Steven R. Pacelli
Executive Vice President, Strategy and Corporate Development
(858) 200-0200

Industry:

DexCom, Inc.

NASDAQ:DXCM
Release Summary
Dexcom Announces Upcoming Virtual Conference Presentations
Release Versions
English

Contacts

DexCom, Inc.
Steven R. Pacelli
Executive Vice President, Strategy and Corporate Development
(858) 200-0200

More News From DexCom, Inc.

Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) announced today results from the CONNECT randomized controlled trial, demonstrating the use of Dexcom G7 leads to clinically and statistically significant reduction in A1C and improvement in glucose control among people with Type 2 diabetes not using insulin compared with a routine care control group using self-monitoring of blood glucose.1 Researchers presented these results today as an oral presentation at the 2026 Scientific Sessions of...

Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) will present new clinical findings, product advancements and strategic business initiatives reinforcing its commitment to improving care for people with all types of diabetes and ushering in a new era of early stage CGM intervention and preventative care at the American Diabetes Association’s Scientific Sessions in New Orleans, June 5-8, 2026. “Dexcom has built a legacy of innovation within the diabetes space and as we look to the future, e...

Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience

SAN DIEGO--(BUSINESS WIRE)--Dexcom, Inc., the global leader in glucose biosensing, today released its inaugural Customer Advisory Council Report, detailing candid feedback from users, caregivers, healthcare professionals and community leaders, along with clear, actionable company commitments to further elevate product performance and user experience. Building on its position as the manufacturer of the most accurate CGM systems1, Dexcom continues to listen, innovate and act on customer insights...
Back to Newsroom